Loading...
Market
What will be Trodelvy's impact on ES-SCLC patient survival rates by end of 2025?
2
Resolution / Starting Odds
Significant Improvement • 25%
Moderate Improvement • 25%
No Change • 25%
Worse Outcomes • 25%
Published clinical trial results and medical journals
Story
FDA Grants Breakthrough Therapy Designation to Trodelvy for ES-SCLC Treatment
Dec 18, 2024, 12:06 PM
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for the second-line treatment of extensive-stage small cell lung cancer (ES-SCLC). This designation is intended to expedite the development and review of drugs that demonstrate substantial improvement over existing therapies for serious or life-threatening conditions. Trodelvy, developed by Gilead Sciences, has shown promise in addressing the needs of patients with ES-SCLC who have limited treatment options. The FDA's decision highlights the potential of Trodelvy to improve outcomes for this patient population.
View original story
Similar markets
European Union • 25%
Japan • 25%
Canada • 25%
Other • 25%
0-5 trials • 25%
6-10 trials • 25%
11-15 trials • 25%
More than 15 trials • 25%
Approval for a new indication • 25%
Rejection of a new application • 25%
Withdrawal of another indication • 25%
No major action • 25%
Yes • 50%
No • 50%
Increase by more than 10% • 25%
Increase by 5-10% • 25%
Increase by less than 5% • 25%
No significant change or decrease • 25%
Less than 10% • 25%
10%-20% • 25%
20%-30% • 25%
More than 30% • 25%
Yes • 50%
No • 50%
Less than 40% • 25%
40% to 50% • 25%
51% to 60% • 25%
More than 60% • 25%